Previous Close | 43.25 |
Open | 42.99 |
Bid | 43.25 x 800 |
Ask | 48.77 x 1200 |
Day's Range | 41.27 - 43.89 |
52 Week Range | 5.95 - 50.78 |
Volume | |
Avg. Volume | 1,252,678 |
Market Cap | 2.227B |
Beta (5Y Monthly) | 1.10 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.86 |
Earnings Date | Mar 26, 2024 - Mar 30, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.86 |
Subscribe to Yahoo Finance Plus to view Fair Value for VERA
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4th to 6th at the Marriott Copley Place in Boston, MA. IgAN Corporate Panel Discussion Details:
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vera Therapeutics fair value estimate is US$46.59 Vera...
BRISBANE, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 6th Annual Guggenheim Biotechnology Conference, which is taking place in New York on February 7th and 8th. Fireside Chat Details: Date:Wednesday, February 7thTime:2:00 PM ET